296 related articles for article (PubMed ID: 11921054)
1. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.
Beck RW; Chandler DL; Cole SR; Simon JH; Jacobs LD; Kinkel RP; Selhorst JB; Rose JW; Cooper JA; Rice G; Murray TJ; Sandrock AW
Ann Neurol; 2002 Apr; 51(4):481-90. PubMed ID: 11921054
[TBL] [Abstract][Full Text] [Related]
2. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
Jacobs LD; Beck RW; Simon JH; Kinkel RP; Brownscheidle CM; Murray TJ; Simonian NA; Slasor PJ; Sandrock AW
N Engl J Med; 2000 Sep; 343(13):898-904. PubMed ID: 11006365
[TBL] [Abstract][Full Text] [Related]
3. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.
CHAMPS Study Group
Am J Ophthalmol; 2001 Oct; 132(4):463-71. PubMed ID: 11589865
[TBL] [Abstract][Full Text] [Related]
4. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
O'Connor P;
Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
[TBL] [Abstract][Full Text] [Related]
5. Acute demyelinating optic neuritis.
Foroozan R; Buono LM; Savino PJ; Sergott RC
Curr Opin Ophthalmol; 2002 Dec; 13(6):375-80. PubMed ID: 12441840
[TBL] [Abstract][Full Text] [Related]
6. The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study).
Galetta SL
J Neuroophthalmol; 2001 Dec; 21(4):292-5. PubMed ID: 11756862
[TBL] [Abstract][Full Text] [Related]
7. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.
Kinkel RP; Dontchev M; Kollman C; Skaramagas TT; O'Connor PW; Simon JH;
Arch Neurol; 2012 Feb; 69(2):183-90. PubMed ID: 21987393
[TBL] [Abstract][Full Text] [Related]
8. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.
O'Connor P; Kinkel RP; Kremenchutzky M
Mult Scler; 2009 Jun; 15(6):728-34. PubMed ID: 19482863
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.
De Stefano N; Comi G; Kappos L; Freedman MS; Polman CH; Uitdehaag BM; Hennessy B; Casset-Semanaz F; Lehr L; Stubinski B; Jack DL; Barkhof F
J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):647-53. PubMed ID: 24292999
[TBL] [Abstract][Full Text] [Related]
11. Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis.
Siddiqui MA; Wellington K
CNS Drugs; 2005; 19(1):55-61; discussion 63-4. PubMed ID: 15651905
[TBL] [Abstract][Full Text] [Related]
12. Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome.
Kinkel RP; Simon JH; O'Connor P; Hyde R; Pace A
Mult Scler Relat Disord; 2014 Nov; 3(6):712-9. PubMed ID: 25891550
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
[TBL] [Abstract][Full Text] [Related]
14. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial.
Filippi M; Rovaris M; Inglese M; Barkhof F; De Stefano N; Smith S; Comi G
Lancet; 2004 Oct 23-29; 364(9444):1489-96. PubMed ID: 15500893
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
16. [Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].
Waubant E; Sloan R; Andersson PB; Goodkin D
Rev Neurol (Paris); 1999; 155 Suppl 2():S20-3. PubMed ID: 10367321
[TBL] [Abstract][Full Text] [Related]
17. Optic neuritis and multiple sclerosis.
Söderström M
Acta Ophthalmol Scand; 2001 Jun; 79(3):223-7. PubMed ID: 11401627
[TBL] [Abstract][Full Text] [Related]
18. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
[TBL] [Abstract][Full Text] [Related]
19. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
Simon JH; Jacobs LD; Campion M; Wende K; Simonian N; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Alam JJ; Fischer JS; Goodkin DE; Granger CV; Lajaunie M; Martens-Davidson AL; Meyer M; Sheeder J; Choi K; Scherzinger AL; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Whitham RH
Ann Neurol; 1998 Jan; 43(1):79-87. PubMed ID: 9450771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
